Where does Denali Therapeutics Inc.'s cash flow data come from?

Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$508.02M+0.9%	-$512.54M-2.8%	-$498.74M-4.1%	-$479.03M-5.5%	-$453.94M-7.4%
Depreciation and amortization	$11.7M+4.6%	$11.18M+10.0%	$10.17M+12.2%	$9.06M+13.9%	$7.96M+2.1%
Stock-based compensation	$97.56M-2.1%	$99.63M-1.1%	$100.76M+0.3%	$100.49M+0.3%	$100.2M-2.6%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	-$12.24M-2,733%	$465K—	——	——	——
Change in other assets	——	——	——	-$3.63M-1,166%	$340K+156%
Other working capital changes	——	——	——	——	$0—
Net cash from operating activities	-$412.34M+0.1%	-$412.6M-3.7%	-$397.78M-13.8%	-$349.62M+4.4%	-$365.54M-5.1%
Capital expenditures	——	——	——	$18.33M-2.7%	$18.84M+18.4%
Net cash from investing activities	$330.99M+29.7%	$255.28M—	——	——	——
Proceeds from issuance of common stock	$20.83M+146%	$8.46M+102%	-$499.25M—	——	——
Payments for finance leases	$3.83M-53.1%	$8.17M-50.4%	$16.48M-57.9%	$39.13M+6.6%	$36.7M+13.5%
Payment of debt issuance costs	——	$324K+33.3%	$243K+50.0%	$162K+100%	$81K—
Net cash from financing activities	$412.02M+118%	$189.22M—	——	——	——
Net increase (decrease) in cash	$330.68M+937%	$31.9M+1,617%	$1.86M—	——	——
Accrued expenses and other liabilities	-$12.24M-2,733%	$465K—	——	——	——
Deferred research and development funding liability	——	——	——	——	——
Increase (Decrease) In Non-Cash Operating Lease Expense	$4.55M+2.1%	$4.45M+2.2%	$4.35M+2.2%	$4.26M+2.2%	$4.17M+2.3%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Investment Income, Amortization of Discount	$7.62M-25.6%	$10.25M-30.6%	$14.78M-30.1%	$21.13M-25.8%	$28.49M-18.9%
Other Noncash Income (Expense)	——	——	——	——	$0—
Finance Lease, Principal Payments	$3.83M-53.1%	$8.17M-50.4%	$16.48M-57.9%	$39.13M+6.6%	$36.7M+13.5%
Proceeds from exercises of stock options and other stock issuances	$14.56M+72.1%	$8.46M-9.9%	$9.39M-34.2%	$14.26M-15.9%	$16.96M-2.5%
Finance Lease Right Of Use Asset Amortization	$3.63M+0.8%	$3.6M+4.3%	$3.45M+16.9%	$2.95M+43.8%	$2.05M+76.1%
Purchases of intangible assets included in accrued expenses and other liabilities	——	——	——	——	——
Proceeds from sale of revenue participation right	——	——	——	——	——
Increase in right-of-use asset due to lessor assets	——	$0-100%	$1.76M-50.0%	$3.53M-33.3%	$5.29M-25.0%
Free cash flow	-$419.23M+0.7%	-$422.1M-2.7%	-$410.85M-11.7%	-$367.95M+4.3%	-$384.38M-5.7%
Free cash flow	-$419.23M+0.7%	-$422.1M-2.7%	-$410.85M-11.7%	-$367.95M+4.3%	-$384.38M-5.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Denali Therapeutics Inc.'s cash flow data come from?: Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.